T3点滴によるARDSの治療 (ARDS+T3)
急性呼吸窮迫症候群(ARDS)の被験者における血管外肺水(EVLW)に対する甲状腺ホルモン(T3)の影響に関する第II相無作為化、介入対非介入、多施設研究
It is hypothesized that instillation of Liothyronine Sodium (T3) into the airspace will be safe, well tolerated, and will increase alveolar fluid clearance and decrease inflammation in patients with ARDS, reflected in improved oxygenation index (OI) and oxygenation saturation index (OSI).
調査の概要
状態
詳細な説明
T3 Therapy in ARDS- Phase 2 Randomized, Unblinded, Intervention versus Non- Intervention Trial. Enrollment 68 participants (50 treatment + 18 control). Purpose- To determine the safety and tolerability of T3 delivery into the lungs of ARDS patients, and to measure the effect of T3 on Oxygenation in ARDS patients. Study Drug- Liothyronine Sodium (T3), 50 mcg will be instilled twice daily via a catheter through the ETT into the airway in a total volume of 10 mL (T3+0.9% sodium chloride), over 5 days (10 total doses), or until extubation, whichever comes first.
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Minnesota
-
Edina、Minnesota、アメリカ、55435
- M Health Fairview Southdale Hospital
-
Minneapolis、Minnesota、アメリカ、55455
- East Bank Hospital - M Health Fairview University of Minnesota Medical Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Study population is critically ill patients requiring mechanical ventilatory support for ARDS in an intensive care unit.
-
Adults (≥18 years of age).
-
Male or female (non-pregnant).
-
Clinical diagnosis of ARDS (all are required):
- Onset: <= 7 days.
- Chest x-ray: Bilateral Patchy Opacities, Infiltrates.
- Mechanical Vent Support: PEEP or CPAP Support >= 5 cm H2O.
- Pulmonary Edema: Not fully explained by cardiogenic etiology.
- Hypoxia: PaO2/FIO2 Ratio <300, or O2Sat/FIO2 Ratio <315.
-
On mechanical ventilatory support.
-
Capable of giving informed consent directly or from the subject's legally authorized representative (LAR) as determined by the site Principal Investigator and/or Sub- Investigators.
Exclusion Criteria:
Patients with any of the following conditions will be excluded from this trial:
-
Inadequate medical history for determining inclusion/exclusion criteria, as determined by the Principal Investigator and/or Sub- Investigators.
-
Unlikely to complete the protocol with clinic follow-up after discharge, as determined by the Principal Investigator and/or Sub- Investigators or hospice status.
-
Prior history of thyroid cancer or hyperthyroidism, per thorough patient/family interviews, review of past medical history, medication list, laboratory test.
-
Prior history of cardiovascular disease defined as:
- Hypertensive crisis in the past 3 months (systolic >200, or diastolic >120 mmHg),
- Sustained ventricular arrhythmia in the past 3 months (duration >30 seconds)
- Coronary artery disease (documented >=70% occlusion untreated in any coronary vessel), as per the 2021 ACC/AHA/SCAI Guidelines for Coronary Artery Revascularization.
- Cardiac-related angina pectoris (>=2 episodes in the past 3 months)
- Myocardial infarction with ischemia on ECG (i.e.,new ST- elevation/depression of >1mm in contiguous leads).
- Peripheral vascular disease (documented >=70% occlusion untreated in any peripheral vessel), as per the 2018 ACC/AHA/SCAI/SIR/SVM Guidelines for Appropriate Use Criteria for Peripheral Artery Intervention.
- Decompensated or symptomatic heart failure (i.e., hospitalized for CHF exacerbation, or a change in CHF medications within two weeks prior)
-
Currently pregnant or breastfeeding.
-
Known allergy to study drug.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment Arm
Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation. |
Study Drug Administration:
|
|
他の:Control arm
Standard of Care |
Standard of Care (SOC) |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
時間枠:baseline
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
baseline
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
時間枠:6 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
6 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
時間枠:12 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
12 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
時間枠:24 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
24 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
時間枠:48 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
48 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
時間枠:72 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
72 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
時間枠:96 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
96 hours post-dose
|
|
Oxygenation: Oxygenation Index (OI), and/or Oxygenation Saturation Index (OSI).
時間枠:120 hours post-dose
|
To assess the efficacy of airway instilled T3 improving oxygenation by reducing OI and OSI in ARDS patients. OI will be measured by mechanical ventilator (FIO2 and Mean Airway Pressure, MAP), and ABG (PaO2). OSI will be measured by mechanical ventilator (FIO2, SpO2 and MAP): OI = (FIO2 x MAP / PaO2). OSI = (FIO2 x MAP / SpO2). |
120 hours post-dose
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
SOC 昇圧剤の投与量
時間枠:ベースラインと5日間
|
ベースラインと5日間
|
|
|
SOC 利尿剤の投与量
時間枠:ベースラインと5日間
|
ベースラインと5日間
|
|
|
人工呼吸器のない日
時間枠:ベースラインと5日間
|
ベースラインと5日間
|
|
|
ICU 自由日
時間枠:ベースラインと5日間
|
ベースラインと5日間
|
|
|
無酸素デー
時間枠:ベースラインと5日間
|
ベースラインと5日間
|
|
|
全死因死亡率
時間枠:ベースラインと5日間
|
ベースラインと5日間
|
|
|
気管切開の配置要件
時間枠:ベースラインと5日間
|
ベースラインと5日間
|
|
|
TSH、合計 T3、フリー T3、フリー T4
時間枠:ベースラインおよび投与後156時間
|
ベースラインおよび投与後156時間
|
|
|
無料 T3、無料 T4
時間枠:ベースラインと5日間
|
ベースラインと5日間
|
|
|
Pulmonary events
時間枠:baseline and 120 hours post-dose
|
Progressive hemoptysis: bright, red blood in streaks, mixed or clots within sputum on suctioning of greater than 30 mL accumulation anytime following the initial and subsequent intratracheal dosing administrations. |
baseline and 120 hours post-dose
|
|
Cardiovascular event 1
時間枠:baseline to 120hours post-dose
|
New sustained ventricular arrhythmia (>30 secs) |
baseline to 120hours post-dose
|
|
Cardiovascular event 2
時間枠:baseline to 120hours post-dose
|
New sustained accelerated junctional arrhythmia (rate >80 bpm) with worsened hypotension (decrease in mean arterial pressure to less than 65mmHg). |
baseline to 120hours post-dose
|
|
Cardiovascular event 3
時間枠:baseline to 120hours post-dose
|
New sustained atrial fibrillation with rapid ventricular response (ventricular rate >160 bpm) with worsened hypotension (decrease in mean arterial pressure to less than 65mmHg). |
baseline to 120hours post-dose
|
|
Cardiovascular event 4
時間枠:baseline to 120hours post-dose
|
Cardiac arrest (pulseless electrical activity, or asystole). |
baseline to 120hours post-dose
|
|
Cardiovascular event 5
時間枠:baseline to 120hours post-dose
|
Hypertensive crisis (systolic pressure of 180 mmHg (or higher), or diastolic pressure of 120 mmHg (or higher) or change in MAP > 20 mmHg with three consecutive measurements over 30 minutes). |
baseline to 120hours post-dose
|
|
SOC pulmonary vasodilator
時間枠:baseline and 5 days
|
yes or no |
baseline and 5 days
|
|
Supplemental oxygen on discharge
時間枠:baseline and 5 days
|
yes or no |
baseline and 5 days
|
|
Discharge disposition
時間枠:baseline and 5 days
|
home, inpatient rehabilitation, long-term acute care hospital (LTACH) |
baseline and 5 days
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:David H Ingbar, MD、University of Minnesota
- スタディディレクター:Timothy P Rich, MD、University of Minnesota
- 主任研究者:Ronald A Reikoff, MD、University of Minnesota
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- PACS-2020-23242
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。